Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

IOVA Iovance Biotherapeutics

Watchlist
6.840
+0.430+6.71%
Close 12/02 16:00 ET
7.690
+0.850+12.43%
Post Mkt Price 12/02 19:59 ET
High
6.890
Open
6.310
Turnover
91.94M
Low
6.280
Pre Close
6.410
Volume
14.07M
Market Cap
1.08B
P/E(TTM)
Loss
52wk High
20.600
Shares
157.84M
P/E(Static)
Loss
52wk Low
5.420
Float Cap
876.59M
Bid/Ask %
-53.85%
Historical High
165.000
Shs Float
128.16M
Volume Ratio
2.90
Historical Low
1.000
Dividend TTM
--
Div Yield TTM
--
P/B
2.74
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
10.98%
Amplitude
9.52%
Avg Price
6.535
Lot Size
1
Float Cap
876.59M
Bid/Ask %
-53.85%
Historical High
165.000
Shs Float
128.16M
Volume Ratio
2.90
Historical Low
1.000
Dividend TTM
--
P/B
2.74
Dividend LFY
--
Turnover Ratio
10.98%
Amplitude
9.52%
Avg Price
6.535
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
CEO: Mr. Frederick G. Vogt, J.D.,PhD
Market: NASDAQ
Listing Date: 02/26/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist